# After moves to protect medical marijuana, Trump asks Congress to save hemp > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/hemp-versus-medical-marijuana-clinical-differences/ > **Published:** 2026-05-19T13:22:15-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:06:07-04:00 > **Clinical Summary:** Dr. Caplan explains hemp versus medical marijuana clinical differences, federal policy impacts, and therapeutic applications for patients and clinicians. --- CED Clinical Relevance  #56Monitored Relevance  Early-stage or contextual signal requiring further evidence before action. ⚒ Cannabis News  |  CED Clinic Policy & RegulationCbd & CannabinoidsAccess & AvailabilityHemp Vs. CannabisClinical Practice Why This Matters Federal hemp policy directly affects the cannabinoid supply chain available to clinicians—from [CBD products](https://cedclinic.com/fda-warning-on-cbd-products/) to minor [cannabinoid formulations](https://cedclinic.com/brazil-cannabis-regulatory-framework-new-medical-rules/). Regulatory clarity on hemp-derived compounds shapes what can be legally prescribed, what patients can access without prescription, and how we counsel on product quality and consistency. Clinical Summary This item reflects ongoing federal legislative activity regarding hemp protection and [medical cannabis access](https://cedclinic.com/medical-marijuana-card-reciprocity/). [Hemp-derived cannabinoids](https://cedclinic.com/indiana-hemp-drug-ban-thc-product-access/) (CBD, CBN, Delta-8, others) operate in a complex regulatory space between the [2018 Farm Bill](https://cedclinic.com/south-carolina-hemp-regulations-thc-edibles-policy-options/) and FDA oversight. The clinical relevance centers on product availability, standardization, and the distinction between hemp-derived and cannabis-derived formulations—which carry different legal and prescribing frameworks despite often similar pharmacology. Dr. Caplan’s Take “Federal hemp policy is ultimately a supply-chain and access question, not a pharmacology question. *What clinicians need is consistency and transparency—whether the cannabinoid products available to patients are tested, labeled accurately, and legally accessible in their state—regardless of whether they came from federally legal hemp or state-licensed cannabis.*” Clinical Perspective 🧠 From a bedside standpoint, ask patients whether they’re using hemp-derived or cannabis-derived products; the distinction matters for legal status and product regulation in their jurisdiction, even if the active ingredient is identical. Congressional action on hemp doesn’t change clinical efficacy data, but it does change what products patients can legally obtain and afford. Monitor your state and federal cannabis scheduling—it shapes your counseling and referral options. 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20After%20moves%20to%20protect%20medical%20marijuana%2C%20Trump%20asks%20Congress%20to%20save%20hemp%20%40drcaplan&url=https%3A//reason.org/commentary/after-moves-to-protect-medical-marijuana-trump-asks-congress-to-save-hemp/)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A//reason.org/commentary/after-moves-to-protect-medical-marijuana-trump-asks-congress-to-save-hemp/)[🦥 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20After%20moves%20to%20protect%20medical%20marijuana%2C%20Trump%20asks%20Congress%20to%20save%20hemp%20--%20via%20%40drcaplan.bsky.social%20https%3A//reason.org/commentary/after-moves-to-protect-medical-marijuana-trump-asks-congress-to-save-hemp/)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) 📰 Source: [https://reason.org/commentary/after-moves-to-protect-medical-marijuana-trump-asks-congress-to-save-hemp/](https://reason.org/commentary/after-moves-to-protect-medical-marijuana-trump-asks-congress-to-save-hemp/) Table of Contents - [FAQ](#FAQ)[What does CED Clinical Relevance #56 indicate?](#What_does_CED_Clinical_Relevance_56_indicate) - [What is the difference between hemp and cannabis?](#What_is_the_difference_between_hemp_and_cannabis) - [What role does CBD play in cannabinoid therapy?](#What_role_does_CBD_play_in_cannabinoid_therapy) - [How do policy and regulations affect cannabis access?](#How_do_policy_and_regulations_affect_cannabis_access) - [What should healthcare providers consider regarding cannabis in clinical practice?](#What_should_healthcare_providers_consider_regarding_cannabis_in_clinical_practice) - [Related](#Related) ## FAQ #### What does CED Clinical Relevance #56 indicate? CED Clinical Relevance #56 represents a “Monitored Relevance” classification, indicating an early-stage or contextual signal. This designation means further evidence is needed before clinical action should be taken. #### What is the difference between hemp and cannabis? Hemp and cannabis are related plants with different legal and chemical profiles. The primary distinction typically involves THC content levels and regulatory classification, which affect their legal status and applications. #### What role does CBD play in cannabinoid therapy? CBD is a major cannabinoid being studied for various therapeutic applications. It is distinct from THC and is often extracted from hemp for medical and wellness purposes. #### How do policy and regulations affect cannabis access? Policy and regulatory frameworks directly impact the availability and accessibility of cannabis and cannabis-derived products. These regulations vary by jurisdiction and affect both clinical and consumer access. #### What should healthcare providers consider regarding cannabis in clinical practice? Healthcare providers should stay informed about current evidence, regulatory status, and access considerations when incorporating cannabis or cannabinoids into clinical practice. Early-stage evidence requires careful evaluation before implementation. [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Former CMO Canna Care Docs (250,000+ patients supervised), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).